GLP-1 Therapy
GLP-1 therapy helps regulate hunger signals so you feel satisfied sooner and stay full longer. By supporting natural appetite control, it allows for steady, sustainable weight management without extreme dieting.
This treatment is designed for individuals who want a structured, clinician-led approach to weight loss, paired with realistic lifestyle guidance and ongoing support.
What to expect
• Reduced appetite and fewer cravings
• Improved portion control
• A personalized plan based on your goals
Frequently Asked Question
What are GLP-1 medications?
GLP-1 receptor agonists are prescription medications that mimic the glucagon-like peptide-1 hormone, which regulates appetite, insulin secretion, and gastric emptying.
Common GLP-1 single agonists include:
Semaglutide (Wegovy®️, Ozempic®️)
Liraglutide (Saxenda®️, Victoza®️)
These medications primarily reduce appetite and improve glucose regulation.
What is the difference between GLP-1, GLP-1/GIP, and GLP-1/GIP/Glucagon therapies?
GLP-1 (Single Agonist)
Examples: Semaglutide, Liraglutide
Primary action: Appetite suppression, delayed gastric emptying, improved insulin response.
GLP-1/GIP (Dual Agonist)
Example: Tirzepatide (Mounjaro®️, Zepbound®️)
Targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual pathway may enhance insulin sensitivity and metabolic efficiency.
GLP-1/GIP/Glucagon (Triple Agonist – Investigational)
Examples under clinical investigation include Retatrutide.
These aim to influence appetite control (GLP-1), insulin modulation (GIP), and energy expenditure (glucagon receptor activity). Most triple agonists remain in clinical trials and are not standard first-line therapies.
Each category differs in mechanism, data maturity, and side effect profile.
What are the potential benefits?
When medically appropriate, these therapies may support:
Reduced appetite and caloric intake
Improved blood glucose regulation
Significant weight reduction
Reduction in visceral adiposity
Improved cardiometabolic risk markers
Therapy is individualized and monitored.
What are the risks?
Common side effects include nausea, constipation, reflux, and delayed gastric emptying. Rare but serious risks include pancreatitis and gallbladder complications. Contraindications include personal or family history of medullary thyroid carcinoma and MEN2.
We perform comprehensive screening before prescribing.